Baicalein selectively induce apoptosis in human leukemia K562 cells.
- Author:
Qing-hua DONG
1
;
Shu ZHENG
;
Rong-zhen XU
;
Qing-hua LÜ
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Agents, Phytogenic; pharmacology; Apoptosis; drug effects; Caspase 3; Caspases; metabolism; Cell Cycle; drug effects; Flavanones; Flavonoids; pharmacology; Humans; K562 Cells; Proto-Oncogene Proteins c-bcl-2; metabolism; Up-Regulation
- From: Acta Pharmaceutica Sinica 2003;38(11):817-820
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo study the antitumor effect of baicalein on human leukemia K562 cell and its mechanism.
METHODSThe IC50 value and cytotoxity of K562 cell were detected by MTT method. The apoptotic cell was analyzed by FCM using Annexin V FITC--PI staining method. Sub-G1 peak was also measured by FCM. Protein expressions of Bcl-2, Fas, Caspase 3 were evaluated with FCM.
RESULTSBaicalein was shown to significantly inhibit the proliferation of K562 cell in a dose-dependent manner and selectively induce apoptosis of human leukemia K562 cells. Flow cytometric analysis showed that baicalein arrested K562 cells in the S phase. In addition, protein expression of Fas, Caspase 3 of K562 cells increased after exposure to baicalein, but Bcl-2 was unchanged.
CONCLUSIONBaicalein can selectively induce apoptosis of human leukemia K562 cell dose and time dependently through up-regulation of caspase-3 and fas gene expression level.
